Sort   by:  
 Page size 
UnknownPatient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naive Metastatic Renal Cell Carcinoma.
Not available
S-EPMC8407399 | biostudies-literature
UnknownPhase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Not available
S-EPMC3532390 | biostudies-literature
UnknownBehavioral implications of temporal lobe epilepsy on social contingency.
Not available
S-EPMC7484312 | biostudies-literature
UnknownAMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
Not available
S-EPMC4666535 | biostudies-literature
UnknownA phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
Not available
S-EPMC4311191 | biostudies-literature
UnknownConvergent CDR3 homology amongst Spike-specific antibody responses in convalescent COVID-19 subjects receiving the BNT162b2 vaccine.
Not available
S-EPMC8897198 | biostudies-literature
UnknownRandomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma.
Not available
S-EPMC5569691 | biostudies-literature
UnknownMolecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.
Not available
S-EPMC8436590 | biostudies-literature
UnknownRandomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.
Not available
S-EPMC6018511 | biostudies-literature
UnknownPhase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
Not available
S-EPMC2860433 | biostudies-literature
Sort   by:  
 Page size